COMMUNIQUÉS West-GlobeNewswire

Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung Cancer
29/05/2024
Efficacy and safety of AFM24 in combination with atezolizumab, a checkpoint inhibitor, is being evaluated in non-small cell lung cancer patients with EGFR wild-type and EGFR mutant advanced/metastatic cancers in the [...]
Listen in on ALK’s Capital Markets Day on 4 June 2024
29/05/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ) will host a Capital Markets Day on 4 June at 13.00-17.00. We cordially invite investors, analysts, and other interested stakeholders to listen in on our Capital Markets Day 2024, [...]
Curium Extends Irradiation Partnership With NRG I PALLAS in Netherlands for Continuous Supply of Lutetium-177 to Treat 1,000s of Cancer Patients Each Year
29/05/2024
PARIS, May 29, 2024 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, today announced that it has signed a long-term agreement to extend its current partnership with NRG I PALLAS for new irradiation [...]
Cytosurge's CellEDIT Workflow, based on its Proprietary FluidFM® Technology, Receives Validation in Peer-Reviewed Publication
29/05/2024
CellEDIT Service represents a novel workflow leveraging FluidFM-mediated intranuclear nanoinjection of CRISPR/Cas9 components into single cells. Control of the amount and stoichiometry of RNP complexes could boost [...]
Anaveon announces IND approval of ANV600-001 (EXPAND) Phase I/II clinical study
29/05/2024
ANV600 combines a non-blocking α PD-1 antibody and an IL-2Rβ/γ selective agonist targeting IL-2 to tumor-specific T cells resulting in proliferation and increase of tumor-killing potential BASEL, Switzerland, May 29, [...]
Burning Rock Reports First Quarter 2024 Financial Results
29/05/2024
GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR and LSE: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) [...]
FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
29/05/2024
Priority Review recognises the best-in-class potential of the inavolisib-based regimen for patients in urgent need of new treatment options 1,2 Additional analyses of INAVO120 will be presented in an oral abstract [...]
Smart for Life Announces Updates on Successful Completion of Restructuring Program
29/05/2024
Program Has Provided Material Loss Reductions and Transformation of the Company’s Balance Sheet; Company Provides Update on Timing for Form 10-Q MIAMI, May 28, 2024 (GLOBE NEWSWIRE) -- Smart for Life, Inc. (Nasdaq: SMFL [...]
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
28/05/2024
FREMONT, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical Products [...]
Assure Holdings Receives Notification of Delinquency from Nasdaq
28/05/2024
DENVER, May 28, 2024 (GLOBE NEWSWIRE) -- Assure Holdings Corp. (the “ Company ” or “ Assure ”) (NASDAQ: IONM), a provider of intraoperative neuromonitoring (“ IONM ”) and remote neurology services, today announced that [...]
Cronos Terminates Sale-Leaseback of Peace Naturals Campus
28/05/2024
TORONTO, May 28, 2024 (GLOBE NEWSWIRE) -- Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos” or the “Company”) announced today that it has terminated its agreement (the “Sale Agreement”) with Future Farmco Canada [...]
UPDATE – Ikena Oncology Announces Strategic Update
28/05/2024
Ikena to discontinue development of IK-930 IK-595 dose escalation continues in RAS and RAF mutant cancers; Encouraging PK and PD profile shown to date Ended first quarter with $157.3 million; Exploring strategic options [...]
Cellectis publie ses résultats financiers du premier trimestre 2024
28/05/2024
• Cellectis annonce la réalisation de l’investissement additionnel d’AstraZeneca • Situation de trésorerie de 143 millions de dollars au 31 mars 2024 1 , projection de la trésorerie jusqu’en 2026 2 • Conférence [...]
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
28/05/2024
Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth ALACHUA, Fla. and TAMPA, Fla., May 28, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing [...]
Cellectis Reports Financial Results for First Quarter 2024
28/05/2024
• Cellectis announced completion of the additional equity investment of $140M by AstraZeneca • Cash position of $143 million as of March 31, 2024 1 ; cash runway projection into 2026 2 • Conference call and webcast [...]
Information on the Total Number of Voting Rights and Shares
28/05/2024
REGULATED INFORMATION Information on the Total Number of Voting Rights and Shares Mont-Saint-Guibert (Belgium), May 28, 2024, 10:30 pm CET / 4:30 pm ET – In accordance with article 15 of the Law of 2 May 2007 on the [...]
Informations sur le Nombre Total de Droits de Vote et d'Actions
28/05/2024
INFORMATION RÉGLEMENTÉE Informations sur le Nombre Total de Droits de Vote et d'Actions Mont-Saint-Guibert (Belgique), le 28 mai 2024, 22:30h CET / 16:30h ET – Conformément à l'article 15 de la loi du 2 mai 2007 [...]
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
28/05/2024
New data from the completed dose escalation part and ongoing expansion part of Study 1100, an ongoing US Phase 1 study evaluating NBTXR3 followed by anti-PD-1 in patients with recurrent or metastatic head and neck [...]
NANOBIOTIX annonce une présentation de nouvelles données et du programme d’immunothérapie de Phase 1 lors de la réunion annuelle 2024 de l’American Society for Clinical Oncology (ASCO) suivi d’une conférence téléphonique et webcast
28/05/2024
Nouvelles données de la partie escalade de dose terminée et de la partie expansion en cours de l’étude 1100, une étude de Phase 1 en cours aux Etats-Unis, évaluant NBTXR3 suivi d’un anti-PD-1 chez des patients atteints [...]

Pages